LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- Stellar
Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a
key protein utilized in multiple immunotherapy development
pipelines targeting cancers, Alzheimer's and lupus, among other
diseases, today issued a statement congratulating Neovacs S.A. for
its decision to extend the development of its lupus drug for Type 1
diabetes.
Neovacs, a collaboration partner utilizing Stellar's KLH protein
as a carrier molecule for its Kinoid treatment, announced in a
press release that it would begin preclinical proof-of-concept
studies in diabetes this year, with the objective of entering
clinical studies in the first half of 2018. Type 1 diabetes is an
autoimmune disease, which affects 25 million people worldwide,
according to the World Health Organization. Lupus affects
approximately 5 million people globally.
"We extend our congratulations to Neovacs on this promising news
and the continuing advancement of their Kinoid technology," said
Stellar President and CEO Frank
Oakes. "The large patient populations of lupus, and now
diabetes, underscore the need for us to prepare Stellar to be in a
position to provide significantly larger supplies of our
pharmaceutical-grade KLH products."
To this end, Stellar has ongoing initiatives to expand its
infrastructure and production capacity to manufacture
multi-kilogram quantities of its Stellar KLH products. In addition,
last year, Stellar and Neovacs announced formation of a joint
venture, Neostell S.A.S., for manufacturing immunotherapy products
for Neovacs and potentially other third-party customers utilizing
KLH-based therapeutic vaccines. Therapeutic vaccines represent a
new class of treatments, known as active immunotherapies, which are
designed to stimulate a patient's own immune system to generate an
immune response to target and attack an existing disease or
condition.
About Stellar Biotechnologies
Based north of
Los Angeles at the Port of
Hueneme, Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader
in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an
important immune-stimulating protein used in wide-ranging
therapeutic and diagnostic markets. KLH is both an active
pharmaceutical ingredient (API) in many new immunotherapies
(targeting cancer, immune disorders, Alzheimer's and inflammatory
diseases) as well as a finished product for measuring immune
status. Stellar is unique in its proprietary methods, facilities,
and KLH technology. The company is committed to meeting the growing
demand for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based
active immunotherapies. Stellar KLH is a trademark of Stellar
Biotechnologies.
Follow Stellar: LinkedIn | Twitter | Facebook | Google+
Stellar Forward-Looking Statements
This press
release may contain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by the use of words
such as "anticipate," "believe," "plan," "estimate," "expect,"
"intend," "may," "will," "would," "could," "should," "might,"
"potential," or "continue" and variations or similar expressions.
Readers should not unduly rely on these forward-looking statements,
which are not a guarantee of future performance. There can be no
assurance that forward-looking statements will prove to be
accurate, as all such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause
actual results or future events to differ materially from the
forward-looking statements. Such risks include, but may not be
limited to: general economic and business conditions; technology
changes; competition; changes in strategy or development plans;
availability of funds and resources; anticipated requirements for
operating capital; governmental regulations and the ability or
failure to comply with governmental regulations; changes in trade
policy and international law; the timing of Stellar's or its
partners' anticipated results, including in connection with
clinical trials; the ability to meet the goals of Stellar's joint
ventures and strategic partnerships; and other factors
referenced in Stellar's filings with securities regulators. For a
discussion of further risks and uncertainties related to the
Stellar's business, please refer to Stellar's public company
reports filed with the U.S. Securities and Exchange Commission and
the British Columbia Securities Commission. All forward-looking
statements are made as of the date hereof and are subject to
change. Except as required by law, Stellar assumes no obligation to
update such statements. This press release does not constitute an
offer or solicitation of an offer for sale of any securities in any
jurisdiction, including the United
States.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/stellar-biotechnologies-congratulates-partners-decision-to-extend-drug-development-for-diabetes-300402048.html
SOURCE Stellar Biotechnologies, Inc.